Welcome to a New Era in Detection

Qorvo Biotechnologies brings a unique approach to the health diagnostics testing landscape. Using Bulk Acoustic Wave (BAW) technology, the Qorvo Omnia™ platform is designed to deliver rapid results for SARS-CoV-2 antigen and antibody tests.

Learn More

Have a Qorvo Omnia instrument?

Access Self-Service Support
Omnia device graphic

Qorvo Biotechnologies Omnia™ SARS-CoV-2 Antigen Test Detects Delta and Other Circulating COVID-19 Variants

Read The White Paper
  • Fast

    Results in approximately 20 minutes

  • Versatile

    Antibody and Antigen cartridges tested on the same instrument

  • Easy to Use

    3 simple steps

Designed to Achieve Rapid Test Results for SARS-CoV-2 Infection

This video gives a simple technical overview of Qorvo’s biotech platform. Please visit https://www.qorvo.com/innovation/biotechnologies to read the latest news regarding our work in veterinary and human testing.

Using Bulk Acoustic Wave (BAW) technology, the Qorvo Omnia platform is designed to deliver rapid test results for SARS-CoV-2 infections. BAW enables surface-based mass measurement using high frequency and surface binding. BAW allows for multi-plexing (multiple analytes from a single sample) and the test cartridge is designed to measure across multiple sample matrices such as whole blood, serum, plasma, saliva and more.

Collecting and Processing Specimens

Step 1

Add Sample

Step 2

Insert Cartridge

Step 3

Report Results

The system's ease of use and rapid turnaround time of results enables a clinician's access to test data in minutes.

Access Self Service Support

SARS-CoV-2 Solutions
A New Era in SARS-CoV-2 Diagnostic Testing

The Qorvo Biotechnologies Omnia instrument and test cartridge system is an immunoassay testing format that utilizes an innovative Bulk Acoustic Wave (BAW) detection technology to deliver rapid test results for SARS-CoV-2.

Antigen Test*

  • Low limit of SARS-CoV-2 detection
  • 100% Specificity; 89.5% Sensitivity
  • Qualified using nasal swabs

IgG Antibody Test**

  • Detects both S1 and nucleocapsid
  • Quantifiable results with antibody level compared to cut-off value
  • Qualified using serum, plasma and whole blood samples

*This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
**These statements reflect the data submitted to the FDA under the EUA process. The Qorvo Biotechnologies IgG Antibody Test has not been reviewed by the FDA and is not available for sale. An application for Emergency Use Authorization (EUA) of this test has been submitted to the FDA and is pending. The application is for use of the test in CLIA laboratories certified to perform moderate- and high-complexity testing.

Self Service Support

Click below to access Qorvo Omnia instrument and test documents.

Access Self Service Support

For immediate technical support:

Call
1-833-384-1522
Email
Email Support OmniaCOVID19Test@qorvo.com

Qorvo BAW Technology

Learn how Qorvo Bulk Acoustic Wave (BAW) technology is revolutionizing the diagnostic testing landscape.

News and Events

Here you'll find the latest news and information from Qorvo Biotechnologies. Browse through our press releases, latest videos, upcoming events and related content.

Contact Us

Please submit the form so we can get back to you.